LU93078I2 - Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib - Google Patents

Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib Download PDF

Info

Publication number
LU93078I2
LU93078I2 LU93078C LU93078C LU93078I2 LU 93078 I2 LU93078 I2 LU 93078I2 LU 93078 C LU93078 C LU 93078C LU 93078 C LU93078 C LU 93078C LU 93078 I2 LU93078 I2 LU 93078I2
Authority
LU
Luxembourg
Prior art keywords
solvates
pharmaceutically acceptable
acceptable salts
combimetinib
possibly
Prior art date
Application number
LU93078C
Other languages
English (en)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37728416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of LU93078I2 publication Critical patent/LU93078I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU93078C 2005-10-07 2016-05-19 Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib LU93078I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72457805P 2005-10-07 2005-10-07
US80284006P 2006-05-23 2006-05-23
PCT/US2006/039126 WO2007044515A1 (fr) 2005-10-07 2006-10-05 Inhibiteurs de mek et procedes pour les utiliser

Publications (1)

Publication Number Publication Date
LU93078I2 true LU93078I2 (fr) 2016-07-19

Family

ID=37728416

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93078C LU93078I2 (fr) 2005-10-07 2016-05-19 Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib

Country Status (32)

Country Link
US (9) US7803839B2 (fr)
EP (1) EP1934174B1 (fr)
JP (8) JP5129143B2 (fr)
KR (2) KR20130058072A (fr)
CN (5) CN103524392B (fr)
AT (1) ATE504565T1 (fr)
AU (1) AU2006302415B2 (fr)
BE (1) BE2016C029I2 (fr)
BR (1) BRPI0617165B1 (fr)
CA (3) CA2622755C (fr)
CY (2) CY1111670T1 (fr)
DE (1) DE602006021205D1 (fr)
DK (1) DK1934174T3 (fr)
EA (3) EA025871B9 (fr)
ES (1) ES2365070T3 (fr)
FR (1) FR16C0021I2 (fr)
GE (1) GEP20125456B (fr)
HR (1) HRP20110498T1 (fr)
HU (1) HUS1600021I1 (fr)
IL (5) IL189900A (fr)
LT (1) LTC1934174I2 (fr)
LU (1) LU93078I2 (fr)
MY (1) MY162174A (fr)
NL (1) NL300809I2 (fr)
NO (4) NO347091B1 (fr)
NZ (1) NZ567140A (fr)
PL (1) PL1934174T3 (fr)
PT (1) PT1934174E (fr)
RS (1) RS51782B (fr)
SI (1) SI1934174T1 (fr)
WO (1) WO2007044515A1 (fr)
ZA (1) ZA200802075B (fr)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
CN103524392B (zh) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
CA2658725A1 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek
EP2113500A1 (fr) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited Inhibitêur du kinàse MAPK/ERK
ES2703723T3 (es) * 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
WO2008124085A2 (fr) * 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
MX2009011998A (es) * 2007-05-10 2009-11-19 Pfizer Ltd Derivados de azetidina y su uso como antagonistas de prostaglandina e2.
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2010003025A1 (fr) 2008-07-01 2010-01-07 Genentech, Inc. Hétérocycles bicycliques en tant qu'inhibiteurs de mek kinase
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
EP2370568B1 (fr) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mutations de mek conférant une résistance aux inhibiteurs de mek
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2772691C (fr) 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Composes de benzoxazepine inhibiteurs de pi3k et leurs procedes d'utilisation
AU2010299820A1 (en) 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
NZ599939A (en) * 2009-10-12 2014-02-28 Hoffmann La Roche Combinations of a pi3k inhibitor and a mek inhibitor
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
WO2011089400A1 (fr) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibiteurs de la pi3 kinase
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
EP3028699B1 (fr) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Mutations braf conférant une résistance aux inhibiteurs de braf
EP2545187B1 (fr) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Procédés de diagnostic et de traitement du cancer chez des patients ayant ou développant une résistance à une première thérapie anticancéreuse
WO2011121317A1 (fr) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo[1,2-b][1,2,3]thiadiazoles en tant qu'inhibiteurs de la kinase protéique ou de la kinase lipidique
EA201290957A1 (ru) 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
KR101862327B1 (ko) 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
WO2012018638A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
WO2012018639A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
WO2012031004A1 (fr) 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, leur procédé de fabrication et leur méthode d'utilisation
WO2012030990A1 (fr) 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridazinones, leur procédé de fabrication et leur procédé d'utilisation
WO2012052745A1 (fr) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral
EP2640366A2 (fr) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
RU2013138835A (ru) 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
BR112013024122A2 (pt) 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
CN102718750B (zh) * 2011-03-31 2015-03-11 中国人民解放军军事医学科学院毒物药物研究所 含吖啶环的氨基吡啶类衍生物及其用途
KR20140022053A (ko) * 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
EP2524918A1 (fr) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines en tant qu'inhibiteurs de kinase
JP5997763B2 (ja) 2011-05-19 2016-09-28 フンダシオン セントロ ナシオナル デ インベスティガシオネス オンコロヒカス カルロス ザ サードＦｕｎｄａｃｉｏｎ Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ Ｃａｒｌｏｓ ＩＩＩ タンパク質キナーゼ阻害剤としての大環状化合物
MX2013014151A (es) 2011-06-03 2014-01-23 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k.
EP2739358B1 (fr) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de mek
KR20140071361A (ko) 2011-08-12 2014-06-11 에프. 호프만-라 로슈 아게 피라졸로[3,4-c]피리딘 화합물 및 사용 방법
CA2845191A1 (fr) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Composes de type pyrazol-4-yl-heterocyclyl-carboxamide et leurs methodes d'utilisation
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
PH12014500925A1 (en) * 2011-10-28 2014-06-09 Genentech Inc Therapeutic combinations and methods of treating melanoma
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
US8669251B2 (en) 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EA027561B1 (ru) 2011-11-03 2017-08-31 Ф.Хоффманн-Ля Рош Аг Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
EP2592103A1 (fr) 2011-11-08 2013-05-15 Adriacell S.p.A. Dérivés d'aldéhyde de polymère
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
WO2013082511A1 (fr) 2011-12-02 2013-06-06 Genentech, Inc. Procédés pour surmonter la résistance tumorale aux antagonistes de vegf
CN103204822B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
CA2863427C (fr) 2012-02-01 2022-07-12 The Governors Of The University Of Alberta Utilisation de pdgfr-alpha en tant que marqueur de diagnostic pour le cancer de la thyroide papillaire
WO2013169858A1 (fr) 2012-05-08 2013-11-14 The Broad Institute, Inc. Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
CA2871388A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Composes 5-azaindazole et methodes d'utilisation
RU2015106673A (ru) 2012-08-02 2016-09-20 Дженентек, Инк. Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
US9463251B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
ES2765573T3 (es) 2012-08-13 2020-06-09 Univ Rockefeller Tratamiento y diagnóstico de melanoma
JP6335169B2 (ja) 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
EP2890698B1 (fr) 2012-08-30 2017-03-01 F. Hoffmann-La Roche AG Composés dioxino- et oxazine-[2,3-d]pyrimidine, inhibiteurs de pi3k, et leurs procédés d'utilisation
WO2014048939A1 (fr) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Composés d'éther cyclique-pyrazol-4-yl-hétérocyclyl-carboxamide et procédés d'utilisation
JP2015533832A (ja) 2012-10-09 2015-11-26 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
HRP20180670T1 (hr) * 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
BR112015008251B1 (pt) 2012-10-12 2023-09-26 Medimmune Limited Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
EP2906296B1 (fr) 2012-10-12 2018-03-21 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
WO2014074785A1 (fr) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Procédés de prédiction de l'issue et du traitement du cancer du sein
WO2014078669A1 (fr) * 2012-11-15 2014-05-22 Duquesne University Of The Holy Ghost Inhibiteurs de mek sous forme de promédicaments à base d'ester d'acide carboxylique
TW201441193A (zh) 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
EP3249054A1 (fr) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations et procédés pour stabiliser des réactifs pcr
HK1216176A1 (zh) 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
MX2015010682A (es) 2013-02-22 2016-05-31 Stemcentrx Inc Nuevos conjugados de anticuerpos y usos de los mismos.
WO2014133071A1 (fr) 2013-02-27 2014-09-04 第一三共株式会社 Procédé de prédiction de la réactivité à un composé inhibant la voie de transduction du signal de mapk
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
KR20160003652A (ko) 2013-03-15 2016-01-11 캔써 리써치 테크놀로지, 엘엘씨 감마―글루타밀 주기 조절 방법 및 조성물
EP2975936A4 (fr) 2013-03-22 2017-03-15 University of Hawaii Nouveaux inhibiteurs de stats3
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
JP6604942B2 (ja) 2013-06-13 2019-11-13 バイオマトリカ，インク． 細胞安定化
MX2015018038A (es) 2013-07-03 2016-03-16 Hoffmann La Roche Compuestos de heteroaril-piridona y aza-piridona-amida.
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
US9260415B2 (en) 2013-12-05 2016-02-16 Genentech, Inc. Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
CN106573927B (zh) 2014-03-18 2019-09-27 豪夫迈·罗氏有限公司 氧杂环庚烷-2-基-吡唑-4-基-杂环基-甲酰胺化合物和使用方法
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2015166355A2 (fr) 2014-04-18 2015-11-05 The Governors Of The University Of Alberta Thérapie ciblée pour restaurer le transport de l'iode radioactif pour traiter le cancer de la thyroïde
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
US11293915B2 (en) 2014-05-08 2022-04-05 Cornell University Bio-adhesive gels and methods of use
WO2015182734A1 (fr) * 2014-05-30 2015-12-03 協和発酵キリン株式会社 Composé hétérocyclique contenant de l'azote
WO2015191632A1 (fr) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilisation de thrombocytes à des températures ambiantes
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107124870A (zh) 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
WO2016050921A1 (fr) 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Composés de pyrazole-carboxamide destinés à être utilisés dans le traitement de troubles médiés par la tyrosine kinase de bruton (btk)
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma
EP3223854A1 (fr) 2014-11-25 2017-10-04 ADC Therapeutics SA Conjugués anticorps-pyrrolobenzodiazépine
WO2016094837A2 (fr) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
WO2016095088A1 (fr) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
WO2016095089A1 (fr) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016164916A1 (fr) 2015-04-10 2016-10-13 Thomas Jefferson University Procédés et compositions de traitement de cancers et d'amélioration de l'immunité thérapeutique par réduction sélective des monocytes m2 immunomodulateurs
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
IL256299B2 (en) 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
TWI649326B (zh) 2015-07-02 2019-02-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其製備方法
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
EP3370775B1 (fr) 2015-11-03 2023-04-19 Genentech, Inc. Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
PL3377107T3 (pl) 2015-11-19 2020-12-14 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego
KR102589056B1 (ko) 2015-12-08 2023-10-12 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN113925833A (zh) 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (fr) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3443114A1 (fr) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Procédés diagnostiques et thérapeutiques relatifs au cancer
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2017216279A1 (fr) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Modulateurs des récepteurs des œstrogènes hétéroaryles et leurs utilisations
WO2018022933A1 (fr) 2016-07-27 2018-02-01 Obi Pharma, Inc. Compositions de glycanes immunogènes/thérapeutiques et utilisations associées
CN106220607B (zh) * 2016-07-27 2018-09-18 成都百事兴科技实业有限公司 一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
EP3491026A4 (fr) 2016-07-29 2020-07-29 OBI Pharma, Inc. Anticorps humains, compositions pharmaceutiques et procédés
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
WO2018064299A1 (fr) 2016-09-29 2018-04-05 Genentech, Inc. Polythérapie avec un inhibiteur de mek, un inhibiteur de l'axe pd-1 et un taxane
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
CN110300601B (zh) 2017-02-08 2024-01-05 Adc治疗有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN106866624B (zh) * 2017-02-27 2017-12-26 济宁医学院 一种卡比替尼的化学合成方法
EP3606536A4 (fr) 2017-04-04 2020-12-16 University of Miami Biomarqueurs indicatifs du cancer de la prostate et traitement associé
EP3612537B1 (fr) 2017-04-18 2022-07-13 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20190137847A (ko) 2017-04-20 2019-12-11 에이디씨 테라퓨틱스 에스에이 항-cd25 항체-약물 접합체와의 병용 요법
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
JP2020523384A (ja) 2017-06-14 2020-08-06 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５ ａｄｃを投与するための投与レジメ
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
AU2018329925B2 (en) 2017-09-08 2025-05-29 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2019158579A1 (fr) 2018-02-13 2019-08-22 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
EP4470621A3 (fr) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Composition pharmaceutique comprenant un monoester d'acide gras de saccharose
WO2019183320A1 (fr) 2018-03-21 2019-09-26 Colorado State University Research Foundation Compositions de vaccins contre le cancer et leurs méthodes d'utilisation
JPWO2019188595A1 (ja) 2018-03-26 2020-12-03 富士フイルム株式会社 感光性樹脂組成物及びその製造方法、レジスト膜、パターン形成方法、並びに、電子デバイスの製造方法
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
US20210322564A1 (en) 2018-08-31 2021-10-21 Adc Therapeutics Sa Combination therapy
WO2020079581A1 (fr) 2018-10-16 2020-04-23 Novartis Ag Charge mutationnelle tumorale seule ou en combinaison avec des marqueurs immunitaires comme biomarqueurs pour prédire une réponse à une thérapie ciblée
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
MA55141A (fr) * 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7546297B2 (ja) * 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CA3120351A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau
WO2020109251A1 (fr) 2018-11-29 2020-06-04 Adc Therapeutics Sa Régime posologique
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
CA3124330A1 (fr) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combinaison d'un conjugue anticorps-medicament et d'un inhibiteur de kinase
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
CR20210541A (es) 2019-03-29 2021-12-20 Medimmune Ltd Compuestos y conjugados de estos
TWI735210B (zh) 2019-04-26 2021-08-01 中國醫藥大學 Ａｄａｍ９抑制劑作為免疫調節劑之用途
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
AU2020292965A1 (en) 2019-06-10 2022-01-27 Adc Therapeutics Sa Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
CA3142664A1 (fr) 2019-06-10 2020-12-17 Adc Therapeutics Sa Polytherapie comprenant un conjugue anticorps-medicament anti-cd25 et un autre agent
PE20220937A1 (es) 2019-07-22 2022-05-31 Lupin Ltd Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
US20240123081A1 (en) 2019-10-25 2024-04-18 Medimmune, Llc Branched moiety for use in conjugates
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
EP4073025B1 (fr) 2019-12-13 2024-03-27 Inspirna, Inc. Sels métalliques et leurs utilisations
CN111170990B (zh) * 2020-01-16 2021-01-05 广州科锐特生物科技有限公司 一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
CA3166732A1 (fr) 2020-01-22 2021-07-29 Medimmune Limited Composes et conjugues correspondants
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
TW202200146A (zh) 2020-04-10 2022-01-01 日商大鵬藥品工業股份有限公司 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
JP2023521885A (ja) 2020-04-16 2023-05-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ディールス－アルダーコンジュゲーション方法
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
EP3915576A1 (fr) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Récepteurs d'antigène chimérique spécifiques pour p95her2 et leurs utilisations
EP3939999A1 (fr) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
GB202012161D0 (en) 2020-08-05 2020-09-16 Adc Therapeutics Sa Combination therapy
MX2023001865A (es) 2020-08-14 2023-05-09 Guangzhou Lupeng Pharmaceutical Company Ltd Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.
GB202015226D0 (en) 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
GB202015916D0 (en) 2020-10-07 2020-11-18 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4304592A1 (fr) 2021-03-09 2024-01-17 Genentech, Inc. Belvarafénib destiné à être utilisé dans le traitement de cancers du cerveau
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
WO2022251193A1 (fr) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Polythérapies
GB202107709D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
GB202107713D0 (en) 2021-05-28 2021-07-14 Medimmune Ltd Combination therapy
GB202107706D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
MX2023015264A (es) 2021-06-29 2024-01-19 Adc Therapeutics Sa Terapia de combinaicon con conjugados de anticuerpo-farmaco.
WO2023057545A1 (fr) 2021-10-06 2023-04-13 Microquin Ltd. Chalcones substitués
EP4426305A1 (fr) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Nouvelle utilisation d'un composé quinazolinone pour le traitement du cancer
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of pyrrolopyridine-aniline compounds
US20250295796A1 (en) 2021-12-16 2025-09-25 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
US11780800B1 (en) 2022-03-17 2023-10-10 Springworks Therapeutics, Inc. Fluorinated phenylamino compounds and pharmaceutical compositions
EP4253418A1 (fr) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Cellules immunitaires exprimant des récepteurs d'antigène chimérique et anticorps bispécifiques et leurs utilisations
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
US20260048075A1 (en) 2022-08-10 2026-02-19 Vib Vzw Inhibition of TCF4/ITF2 in the Treatment of Cancer
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
EP4406973A1 (fr) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Anticorps et leurs utilisations pour le traitement d'infections provoquées par des virus enveloppés
CN120813358A (zh) 2023-04-06 2025-10-17 卫材R&D管理有限公司 用于治疗肿瘤的药物组合物
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
WO2025029650A1 (fr) 2023-07-28 2025-02-06 Li Xiyan Régimes nutritionnels modifiés comprenant des aminoacides destinés à être utilisés dans le traitement d'une maladie
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026019990A1 (fr) 2024-07-18 2026-01-22 Genentech, Inc. Méthodes de traitement du cancer avec des anticorps bispécifiques anti-ccr8/anti-cd3
WO2026024841A1 (fr) 2024-07-24 2026-01-29 Astellas Us Llc Anticorps bispécifiques qui se lient à cd3 et muc1 et leurs procédés d'utilisation
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
JPH03192592A (ja) 1989-12-21 1991-08-22 Matsushita Electric Ind Co Ltd 磁気テープ記録再生装置
CN1094487C (zh) * 1994-04-01 2002-11-20 盐野义制药株式会社 肟衍生物和含有其作为活性成分的杀菌剂
WO1997012613A1 (fr) 1995-10-05 1997-04-10 Warner-Lambert Company Procede de traitement et de prevention des inflammations et de l'atherosclerose
WO1998037881A1 (fr) 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
AU757046B2 (en) 1997-07-01 2003-01-30 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
JP2002509536A (ja) * 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
TR200101704T2 (tr) 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
HRP20010473A2 (en) 1998-12-22 2002-08-31 Warner Lambert Co Combination chemotherapy
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
DE69924641D1 (de) 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
CA2349180A1 (fr) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4'heteroaryle diarylamines
GEP20032999B (en) 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
KR20020012315A (ko) 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
EP1202732A2 (fr) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Methode de traitement de la douleur chronique utilisant des inhibiteurs mek
AU6068600A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
WO2002006213A2 (fr) * 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10141266A1 (de) * 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
JP2003192592A (ja) 2001-10-17 2003-07-09 Sankyo Co Ltd 医薬組成物
PL370549A1 (en) 2001-10-31 2005-05-30 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2003077855A2 (fr) 2002-03-13 2003-09-25 Array Biopharma, Inc Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek
AU2003238915B2 (en) 2002-06-11 2008-02-21 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
MXPA05009459A (es) * 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1641804A1 (fr) * 2003-06-20 2006-04-05 Celltech R & D Limited Derives de thienopyridone en tant qu inhibiteurs de kinase
WO2005000818A1 (fr) 2003-06-27 2005-01-06 Warner-Lambert Company Llc Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
WO2005007616A1 (fr) * 2003-07-23 2005-01-27 Warner-Lambert Company Llc Derives de diphenylaminocetone utiles comme inhibiteurs de mek
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
BRPI0412851A (pt) * 2003-07-24 2006-10-03 Warner Lambert Co benzamidazóis de n-metila-substituìdos
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005028426A1 (fr) * 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN100509808C (zh) * 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR050084A1 (es) 2004-07-27 2006-09-27 Novartis Ag Derivados de bencimidazolona como inhibidores de hsp90
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
WO2006061712A2 (fr) 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN103524392B (zh) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
CA2658725A1 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek

Also Published As

Publication number Publication date
NO20200035A1 (no) 2008-06-17
RS51782B (sr) 2011-12-31
CN101365676B (zh) 2013-09-11
JP2015232045A (ja) 2015-12-24
US20200283383A1 (en) 2020-09-10
IL189900A0 (en) 2008-08-07
US20170166523A9 (en) 2017-06-15
AU2006302415B2 (en) 2012-09-13
US7915250B2 (en) 2011-03-29
EA025871B9 (ru) 2017-08-31
JP2017101071A (ja) 2017-06-08
IL189900A (en) 2014-06-30
NL300809I2 (fr) 2016-10-19
US7803839B2 (en) 2010-09-28
US8362002B2 (en) 2013-01-29
US20090156576A1 (en) 2009-06-18
EA025871B1 (ru) 2017-02-28
IL260127A (en) 2018-07-31
JP5129143B2 (ja) 2013-01-23
AU2006302415A1 (en) 2007-04-19
KR20130058072A (ko) 2013-06-03
JP2013014601A (ja) 2013-01-24
ATE504565T1 (de) 2011-04-15
NO344876B1 (no) 2020-06-08
HK1214595A1 (zh) 2016-07-29
BRPI0617165B1 (pt) 2023-10-03
US20250100966A1 (en) 2025-03-27
JP2019089841A (ja) 2019-06-13
EP1934174B1 (fr) 2011-04-06
US11597699B2 (en) 2023-03-07
IL229136A0 (en) 2013-12-31
IL233053A0 (en) 2014-07-31
FR16C0021I2 (fr) 2017-04-14
FR16C0021I1 (fr) 2016-06-24
EA019983B1 (ru) 2014-07-30
KR101341792B1 (ko) 2013-12-23
CY2016015I1 (el) 2016-10-05
CA2622755C (fr) 2017-01-31
BRPI0617165A2 (pt) 2015-01-06
NO347091B1 (no) 2023-05-15
CY1111670T1 (el) 2015-10-07
US20200031770A1 (en) 2020-01-30
JP2014111659A (ja) 2014-06-19
CY2016015I2 (el) 2016-10-05
ES2365070T3 (es) 2011-09-21
EA200801041A1 (ru) 2009-02-27
WO2007044515A1 (fr) 2007-04-19
GEP20125456B (en) 2012-03-26
CA2927656C (fr) 2019-09-24
BE2016C029I2 (fr) 2026-01-14
CN103524392B (zh) 2018-06-01
US20110263558A1 (en) 2011-10-27
US20190144382A1 (en) 2019-05-16
HRP20110498T1 (hr) 2011-08-31
US20100249096A1 (en) 2010-09-30
NO20082088L (no) 2008-06-17
CN109053523A (zh) 2018-12-21
US20150141399A1 (en) 2015-05-21
JP5856211B2 (ja) 2016-02-09
JP2020189882A (ja) 2020-11-26
EA201691142A1 (ru) 2017-02-28
CN104892582B (zh) 2019-09-27
HK1119698A1 (en) 2009-03-13
CA3052368A1 (fr) 2007-04-19
IL260127B (en) 2022-04-01
JP2018058907A (ja) 2018-04-12
EA032466B1 (ru) 2019-05-31
SI1934174T1 (sl) 2011-08-31
DK1934174T3 (da) 2011-08-01
NZ567140A (en) 2011-09-30
CA2622755A1 (fr) 2007-04-19
PT1934174E (pt) 2011-07-14
NO2020031I1 (no) 2020-09-04
IL251185A0 (en) 2017-05-29
MY162174A (en) 2017-05-31
DE602006021205D1 (de) 2011-05-19
PL1934174T3 (pl) 2011-09-30
ZA200802075B (en) 2009-08-26
CN109053523B (zh) 2022-03-25
CN101365676A (zh) 2009-02-11
IL229136A (en) 2015-11-30
CN110668988A (zh) 2020-01-10
EA201400111A1 (ru) 2014-09-30
EP1934174A1 (fr) 2008-06-25
LTPA2016016I1 (lt) 2016-06-10
NO2023022I1 (no) 2023-05-11
LTC1934174I2 (lt) 2018-01-10
CN104892582A (zh) 2015-09-09
JP5678019B2 (ja) 2015-02-25
JP2009511490A (ja) 2009-03-19
CA2927656A1 (fr) 2007-04-19
CN103524392A (zh) 2014-01-22
KR20080050601A (ko) 2008-06-09
US20140275527A1 (en) 2014-09-18
HUS1600021I1 (hu) 2016-06-28

Similar Documents

Publication Publication Date Title
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
TW200613243A (en) Novel compounds
IL189666A0 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
MX2010003868A (es) Cis-imidazolinas quirales.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200508207A (en) New benzimidazole derivatives
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
SE0402925D0 (sv) Novel Compounds
TW200639156A (en) New compounds
UA96742C2 (en) Mek inhibitors and use thereof
EA201990219A3 (ru) Ингибиторы mek и способы их применения
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf
UA95250C2 (ru) Пиридинаминосульфонил-замещенные бензамиды как ингибиторы цитохром р450 3а4 (cyp4503a4)